Thomas A. Jandl, MD, PhD, on DLBCL: First-Line Odronextamab Plus Chemotherapy

May 31, 2026 By The ASCO Post Staff

Thomas A. Jandl, MD, PhD, of Stony Brook University Hospital, discusses data from part 1B of the OLYMPIA-3 trial, which showed that among patients with diffuse large B-cell lymphoma (DLBCL), the safety profile of the first-line combination of odronextamab and CHOP chemotherapy was generally manageable and preliminary efficacy was encouraging, with no meaningful differences between regimens. Additionally, combination with odronextamab did not impact the delivery of CHOP (Abstract 7009).

Related Content